Formulation Strategies for Immunomodulatory Natural Products in 3D Tumor Spheroids and Organoids: Current Challenges and Emerging Solutions
Open Access
- 25 September 2025
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 17 (10) , 1258
Abstract
Background/Objectives: Natural products exhibit significant immunomodulatory potential but face severe efficacy loss in three-dimensional (3D) tumor models. This review comprehensively examines the penetration–activity trade-off and proposes integrated strategies for developing effective natural product-based cancer immunotherapies. Methods: We analyzed formulation strategies across three natural product categories (hydrophobic, macromolecular, stability-sensitive), evaluating penetration enhancement versus activity preservation in spheroids, organoids, and advanced 3D platforms. Results: Tumor spheroids present formidable barriers: dense extracellular matrix (33-fold increased fibronectin), pH gradients (7.4 → 6.5), and extreme cell density (6 × 107 cells/cm3). While nanoparticles, liposomes, and cyclodextrins achieve 3–20-fold penetration improvements, biological activity frequently declines through conformational changes, incomplete release (10–75%), and surface modification interference. Critically, immune cells remain peripheral (30–50 μm), questioning deep penetration pursuit. Patient-derived organoids display 68% predictive accuracy, while emerging vascularized models unveil additional complexity. Food and Drug Administration (FDA) Modernization Act 2.0 enables regulatory acceptance of these advanced models. Conclusions: Effective therapeutic outcomes depend on maintaining immunomodulatory activity in peripherally-located immune cell populations rather than achieving maximum tissue penetration depth. Our five-stage evaluation framework and standardization protocols guide development. Future priorities include artificial intelligence-driven optimization, personalized formulation strategies, and integration of multi-organ platforms to bridge the critical gap between enhanced delivery and therapeutic efficacy.Keywords
Funding Information
- Regional Innovation System & Education (RISE) program (2025-RISE-14-003)
This publication has 533 references indexed in Scilit:
- Platycodin D reduces PD‐L1 levels by inhibiting LXR‐β activity and combines with nintedanib to enhance the tumor‐killing effect of T cellsFEBS Letters, 2024
- An Unusual Application of Multifunctional Nanozyme Derived from COF: Augmenting Chemoimmunotherapy while Attenuating CardiotoxicityAdvanced Functional Materials, 2024
- A Flexible Fibrin‐Based Platform for Driving One‐Day Self‐Assembly of Millimeter‐Sized Cell‐Rich Spheroids and Their Applications: An Old Material with New TricksAdvanced Functional Materials, 2024
- Engineered Cell‐Secreted Extracellular Matrix Modulates Cell Spheroid Mechanosensing and Amplifies Their Response to Inductive Cues for the Formation of Mineralized TissuesAdvanced Healthcare Materials, 2022
- Microfluidic Arrays of Breast Tumor Spheroids for Drug Screening and Personalized Cancer TherapiesAdvanced Healthcare Materials, 2021
- Cascade‐Amplifying Synergistic Therapy for Intracranial Glioma via Endogenous Reactive Oxygen Species‐Triggered “All‐in‐One” NanoplatformAdvanced Functional Materials, 2021
- Simultaneous Culturing of Cell Monolayers and Spheroids on a Single Microfluidic Device for Bridging the Gap between 2D and 3D Cell Assays in Drug ResearchAdvanced Functional Materials, 2020
- Designer Exosomes for Active Targeted Chemo‐Photothermal Synergistic Tumor TherapyAdvanced Functional Materials, 2018
- Effect of Shape, Size, and Aspect Ratio on Nanoparticle Penetration and Distribution inside Solid Tissues Using 3D Spheroid ModelsAdvanced Healthcare Materials, 2015
- Microfibrillar structure of PGG-Glucan in aqueous solution as triple-helix aggregates by small angle x-ray scatteringBiopolymers, 1999